Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mind Medicine (MindMed) Inc
Cash & Cash Equivalents
Mind Medicine (MindMed) Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash & Cash Equivalents
$20m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash & Cash Equivalents
$1.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
17%
|
CAGR 10-Years
8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash & Cash Equivalents
CA$371.3m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
34%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Cash & Cash Equivalents
CA$252.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash & Cash Equivalents
$791.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
99%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash & Cash Equivalents
CA$76.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-11%
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
See Also
What is Mind Medicine (MindMed) Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
20m
USD
Based on the financial report for Sep 30, 2025, Mind Medicine (MindMed) Inc's Cash & Cash Equivalents amounts to 20m USD.
What is Mind Medicine (MindMed) Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
2%
Over the last year, the Cash & Cash Equivalents growth was -93%. The average annual Cash & Cash Equivalents growth rates for Mind Medicine (MindMed) Inc have been -49% over the past three years , 2% over the past five years .
